title: Hormone therapy and age-related macular degeneration: the Women's Health Initiative Sight Exam Study.
abstract: OBJECTIVE
  To determine the effectiveness of treatment with conjugated equine estrogens (CEE) or with CEE combined with progestin (CEE + P) on age-related macular degeneration (AMD).
  
  
  METHODS
  In an ancillary study to the Women's Health Initiative clinical trial of hormone therapy, 4262 women 65 years and older underwent fundus photography for the determination of AMD. Participants were recruited from April 2000 to June 2002 at 21 clinical sites an average of 5 years after randomization. Participants were randomized to treatment with CEE, CEE + P, or placebo. Participants had been treated for an average of 5 years at the ophthalmic evaluation for AMD.
  
  
  RESULTS
  The overall prevalence of any AMD was 21.0%. No association was found between CEE + P (odds ratio [OR], 0.91; 95% confidence interval [CI], 0.75-1.11) or CEE alone (OR, 0.98; 95% CI, 0.78-1.25) and early-stage AMD. The CEE + P was associated with a reduced risk of soft drusen (OR, 0.83; 95% CI, 0.68-1.00) after adjustment for covariates and with a reduced risk of neovascular AMD (OR, 0.29; 95% CI, 0.09-0.92).
  
  
  CONCLUSIONS
  Treatment with CEE alone or CEE + P does not affect early- or late-stage AMD. Treatment with CEE + P may reduce the risk of soft drusen or neovascular AMD.
authors.affiliation: Department of Epidemiology, University of Michigan, 611 Church Street, Ann Arbor, MI 48104, USA. mnhaan@umich.edu
authors.forename: Mary N
authors.initials: MN
authors.lastname: Haan
authors.forename: Ronald
authors.initials: R
authors.lastname: Klein
authors.forename: Barbara E
authors.initials: BE
authors.lastname: Klein
authors.forename: Yingzi
authors.initials: Y
authors.lastname: Deng
authors.forename: Lynn K
authors.initials: LK
authors.lastname: Blythe
authors.forename: Johanna M
authors.initials: JM
authors.lastname: Seddon
authors.forename: David C
authors.initials: DC
authors.lastname: Musch
authors.forename: Lewis H
authors.initials: LH
authors.lastname: Kuller
authors.forename: Leslie G
authors.initials: LG
authors.lastname: Hyman
authors.forename: Robert B
authors.initials: RB
authors.lastname: Wallace
mesh_terms: D000368:Aged; D004359:Drug Therapy, Combination; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000008:administration & dosage; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control; D016017:Odds Ratio; D010781:Photography; D017698:Postmenopause; D015995:Prevalence; D011374:Progesterone / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D014481:United States / Q000453:epidemiology; D016387:Women's Health
chemical_list: D004967:Estrogens; D004966:Estrogens, Conjugated (USP); C112940:Progest; D011374:Progesterone